The FDA may have given its blessing to GlaxoSmithKline's melanoma combo Tafinlar and Mekinist. But not so fast, says its counterpart across the pond. The European Medicines Agency (EMA) wants more information, and that has prompted GSK to withdraw its application–for now.
written on 26.03.2014
GlaxoSmithKline yanks European app for Tafinlar-Mekinist combo in melanoma
